Advertisement

Topics

ProQR spins out Amylon Therapeutics for CNS therapeutics

14:38 EDT 13 Sep 2017 | CentreWatch

ProQR Therapeutics has spun out Amylon Therapeutics, a privately-held company focused on the development of therapies for central nervous system (CNS) disorders, with seed funding from a group of institutional and private investors. As part of the transaction, ProQR has granted an exclusive license to Amylon to develop therapeutics for beta amyloid related disorders. Amylon […]

The post ProQR spins out Amylon Therapeutics for CNS therapeutics appeared first on CenterWatch News Online.

Original Article: ProQR spins out Amylon Therapeutics for CNS therapeutics

NEXT ARTICLE

More From BioPortfolio on "ProQR spins out Amylon Therapeutics for CNS therapeutics"

Quick Search
Advertisement
 

Relevant Topics

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...